Outcome of TP53-mutated CCUS and the risk of progression to myeloid neoplasms. Jaktinib in patients (pts) with myelofibrosis (MF) who were intolerant to ruxolitinib (RUX): An open-label, single-arm ...
The study of metabolism within the tumour microenvironment (TME) is a rapidly evolving field that holds significant ...